Abstract 920: Characterization of the orthotopic MMTV PyMT murine mammary carcinoma model following radiation and immune checkpoint blockade

• Published in: Cancer research (Chicago, Ill.) Ill.), 2020-08, Vol.80 (16_Supplement), p.920-920
• Main Authors: Trachet, Erin E., Germain, Derrik Germain, Urs, Sumithra, Draper, David, Franklin, Maryland Rosenfeld
• Format: Article
• Language: English
• ISSN: 0008-5472; 1538-7445
• DOI: 10.1158/1538-7445.AM2020-920

Radiotherapy (RT) is a highly utilized clinical treatment approach for certain types of breast cancer. The use of RT, in combination with checkpoint blockade, to prime and activate the immune system is an area of intensive research. Developing preclinical models for breast cancer research with well characterized tumor immune profiles is highly sought after. MMTV PyMT was originally created as a transgenic mouse model that we have optimized as an orthotopic transplantable model. The baseline immune profile shows an equal distribution of CD8+ and CD4+ T cells, with considerable presence of NK cells. MMTV PyMT tumors have a large myeloid population represented predominantly by granulocytic myeloid-derived suppressor cells and M1 tumor-associated macrophages. In this transplantable model, we tested anti-tumor responses to RT and immunomodulatory agents to determine if the model is more in line with an immunosuppressive “cold” tumor or an immuno-responsive “warm” tumor. Tumor-bearing mice were treated with checkpoint blockade antibodies against PD 1, PD L1, or CTLA 4 alone or in combination with focal RT (SARRP; Xstrahl). Single agent checkpoint inhibitors showed minimal responses while single agent focal RT proved to be highly effective, producing dose dependent tumor regressions at all dosage levels tested (5, 10 & 20Gy). The combination of low dose focal RT (5Gy) with anti CTLA 4 (10mg/kg) resulted in one partial regression and stagnate tumor growth. To examine combination effects on the immune response, we examined infiltration of immune cell types in the tumor using flow cytometry at 2 time points. No remarkable changes occurred in any treatment group, at either time point. Moreover, positive expression of PD 1 remained low, both with and without treatment (